Paul Reynolds

Biography

I gained my PhD in 1997 from the Department of Pathology, University of Bristol, in Keith Brown’s lab. In 1998, I became a postdoctoral fellow in Dr Daniel Haber’s lab at Harvard Medical School/Massachusetts General Hospital Cancer Center, USA and then in 2003 I moved to the University of California, San Francisco in order to work with Dr Thea Tlsty investigating the epigenetic modulation of primary human mammary epithelial cells. I was appointed to a Lectureship at the University of St. Andrews in June 2007. Cancer is a remarkably heterogenous disease and the increasing complexity of molecular changes during tumour evolution highlights the importance of identifying events that drive this process. The Reynolds lab is interested in identifying those molecular changes which drive tumour formation with particular emphasis on 1) novel proteins in the Hippo signaling pathway and 2) resistance mechanisms to therapeutic drugs in cancer. In my lab my colleagues and I are employing biochemistry, molecular biology and cell biology approaches to investigate the nature and context of these factors and how they impact upon carcinogenesis. An understanding of their biology may also contribute to the development of better strategies to identify aggressive tumours early, before the development of metastasis. Another interest is exploring models of physiological tissue settings and disease pathologies where the Hippo pathway plays a role.

Research Interest

His research is focused on novel proteins in the Hippo signaling pathway and resistance mechanisms to therapeutic drugs in cancer.